205 filings
Page 5 of 11
8-K
g9jytmoxz4
4 Jun 21
Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma
9:14am
8-K
ugz6f5
4 Jun 21
Y-mAbs Announces Update on Omburtamab for DIPG
9:12am
8-K
dr27ti h7
19 May 21
Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America
4:15pm
8-K
wzpfksp
13 May 21
Y-mAbs Announces Update on SADA Technology
9:15am
8-K
p3umvs
6 May 21
Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments
4:30pm
DEFA14A
95ncizzm1s3x2w mh
28 Apr 21
Additional proxy soliciting materials
7:33am
8-K
3gdkv5x967 1is
27 Apr 21
Y-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines Agency
4:18pm
8-K
wp9mopfd4e7j1
20 Apr 21
Y-mAbs Provides Regulatory Update on Omburtamab
11:49am
8-K
etu85n0c
12 Apr 21
Y-mAbs Announces GPA33-SADA Data Presented at AACR
9:20am
8-K
lu7dugq9tat 27i
25 Feb 21
Y-mAbs Announces 2020 Financial Results and Recent Corporate Developments
4:15pm
8-K
ksncuq 1h
22 Feb 21
Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
4:15pm
8-K
pk02bg6xvfqss72g
19 Feb 21
Y-mAbs Announces Proposed Public Offering of Common Stock
6:01am
424B5
7plrh0b22 3ams95ma4
18 Feb 21
Prospectus supplement for primary offering
5:22pm
424B5
v98l1 t7b
17 Feb 21
Prospectus supplement for primary offering
6:02am
8-K
m29k fsag9ayd5ywd
22 Jan 21
Completion of Acquisition or Disposition of Assets
6:02am
8-K
1ffe7b14
28 Dec 20
Y-mAbs Announces Sale of Priority Review Voucher
1:20pm
8-K
cqzz 42l67dij7
22 Dec 20
Entry into a Material Definitive Agreement
5:15pm